HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

This month's Leading Edge editorial discusses the difference between perception of risk and the actual risk by drawing upon two recent examples: breast cancer and the pill, and cannabis smoking and cancer risk. In both situations, scientific evidence does not appear to be affecting the public's misperception of absolute risk, and more worryingly, in the case of cannabis smoking, even nationwide policy is being lead by personal views rather than scientific evidence.

The editorial concludes: "Unravelling a misguided perception of risk from the real facts is a difficult task, but it is essential if the perpetuation of poorly conceived ideas is to stop. In light of the current trend towards chemoprevention to reduce a person's risk of contracting cancer, it is important that the general public do not become disenfranchised from the medical community by exposure to over-reporting of contradictory reports in the popular media. Only then will cancer risk truly decrease by informed changes in lifestyle."

Reviews:

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention

Cigarette smoking and the risk of endometrial cancer

Strategic marketing in the UK tobacco industry

Hyperthermia in combined treatment of cancer

Metastasis to and from the central nervous system-the "relatively protected site"

Stem-cell origin of metastasis and heterogeneity of solid tumours

The Lancet Infectious Diseases (TLID)

Combination antiretroviral therapies are widely used for the treatment of HIV but it is unclear whether they will continue to be effective in the face of quickly evolved drug-resistant strains of HIV, and increased risky sexual behaviour in certain communities. In the August issue of The Lancet Infectious Diseases, J X Velasco-Hernandez and colleagues, from the Instituto Mexicano del Petroleo, San Bartolo, Mexico, and the UCLA School of Medicine, Los Angeles, US
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
31-Jul-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO and the Lancet Infectious Diseases TLID

(Date:7/7/2015)... ... July 07, 2015 , ... A ... facial rejuvenation that have emerged about Hillary Clinton. Two plastic surgeons consulted by ... more youthful than she has in some time and speculate that she might ...
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's headquarters ... facility is a state of the art building, located with easy access to New ... founder, said, "We are pleased to service our clients from such a premier location ...
(Date:7/7/2015)... ... July 07, 2015 , ... Safe Catch is setting revolutionary purity limits for ... Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers Market and Wegmans are some of ... to test every fish for mercury,” said Safe Catch co-founder Sean Wittenberg. “We launched ...
(Date:7/7/2015)... ... July 07, 2015 , ... Parents and guardians of teenagers or young ... an open-ended holistic treatment center for drug and alcohol abuse located in Southwest Michigan. ... Research has shown a significant increase in the “club drug” use among high school ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... ... promotion on teeth whitening treatments. A professional teeth whitening is one of the fastest, ... appearance, as well as they can decrease smile satisfaction and confidence. With the right ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3
(Date:7/7/2015)... NEW YORK , July 7, 2015 ... new generation of drugs within human and veterinary oncology, ... the Securities and Exchange Commission, in connection with the ... the NASDAQ Stock Market. The number of American Depositary ... price range for the offering have not yet been ...
(Date:7/7/2015)... July 7, 2015  Monopar Therapeutics LLC, an emerging ... that its co-founder and CEO, Chandler D. Robinson ... U.K. Alumni Entrepreneurial Award. The British Council selected one ... India , and the ... made by entrepreneurs who have leveraged their U.K. education ...
(Date:7/7/2015)... DIEGO , July 7, 2015   ... announced today initiation of enrollment and dosing of ... study of ABX-1431, a first-in-class, investigational endocannabinoid system ... platform, which finds new small molecule drug candidates ... enzymes with important regulatory roles in human physiology ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3
Cached News: